Ra Pharmaceuticals, Inc.
If you purchased Ra Pharmaceuticals, Inc. securities and would like to join the action, please click "Join This Action" below.
RA MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF RA PHARMACEUTICALS, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – RARX
October 10, 2019.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Ra Pharmaceuticals, Inc. (NASDAQ: RARX) to UCB, Inc. (“UCB”) for $48.00 per share is fair to Ra shareholders. On behalf of Ra shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
The Ra merger investigation concerns whether Ra and its Board of Directors violated the federal securities laws and/or their fiduciary duties to shareholders by failing to: (1) obtain the best possible price for Ra shareholders; (2) determine whether UCB is underpaying for Ra; and (3) disclose all material information necessary for Ra shareholders to adequately assess and value the merger consideration.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.